Stocks Comparison
Pharma-Bio Serv vs Vertical Data: revenue, profit, margins and growth compared
Pharma-Bio Serv brought in $9M of revenue in fiscal 2025, Vertical Data $3.7M in fiscal 2025. Pharma-Bio Serv kept -1.1% of its revenue as net profit, Vertical Data -104.2%. Free cash flow was -$221.5K at Pharma-Bio Serv and -$1.5M at Vertical Data.
Side by side, latest fiscal year
| PBSV | VDTA | |
|---|---|---|
| Fiscal year ended | FY2025 (October 31, 2025) | FY2025 (September 30, 2025) |
| Revenue | $9M | $3.7M |
| Revenue growth | -5.3% | n/a |
| Net income | -$100.5K | -$3.8M |
| Net margin | -1.1% | -104.2% |
| Free cash flow | -$221.5K | -$1.5M |
| Free cash flow margin | -2.5% | -39.6% |
| Earnings per share (diluted) | -$0.00 | -$0.09 |
| Cash | $3.4M | $372.7K |
| Debt | n/a | n/a |
| Price to earnings | n/a | n/a |
| Market value | $11.5M | $40.9M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #510 of 603 · Industrials | #538 of 603 · Industrials |
Over the years
PBSV $9MVDTA $3.7M
PBSV -$100.5KVDTA -$3.8M
PBSV -1.1%VDTA -104.2%
PBSV -5.3%VDTA
PBSV -$221.5KVDTA -$1.5M
Questions about Pharma-Bio Serv and Vertical Data
Which is bigger by revenue, Pharma-Bio Serv or Vertical Data?
Pharma-Bio Serv is bigger by revenue: $9M in fiscal 2025, against $3.7M for Vertical Data in fiscal 2025.
Which keeps more of its revenue as profit, Pharma-Bio Serv or Vertical Data?
Pharma-Bio Serv had a net margin of -1.1% in fiscal 2025; Vertical Data had -104.2% in fiscal 2025.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.